Table 2.
Univariate analysis of cumulative incidence of clinically significant (II–IV) acute GVHD in association with patient enhancer and insulator HPSE gene SNPs.
| SNPs | Genotype | Cumulative Incidence, (95% CI), % | χ2, p Value |
|---|---|---|---|
|
rs4693608 (enhancer) |
AA | 47.9 (41.2–55.5) | 15.55 |
| AG | 39.4 (34.2–45.4) | ||
| GG | 29.1 (22.4–37.8) | 0.00042 | |
|
rs4693084 (enhancer) |
GG | 42.0 (37.2–47.4) | 5.4 |
| GT | 38.8 (32.3–46.5) | ||
| TT | 17.5 (7.9–38.9) | 0.067 | |
|
rs4426765 (insulator) |
AA | 42.2 (37.1–47.9) | 2.97 |
| AC | 37.1 (31.1–44.1) | ||
| CC | 34.6 (23.5–50.9) | 0.23 | |
|
rs28649799 (insulator) |
AA | 38.5 (34.4–43.1) | 3.78 |
| AG | 42.8 (34.2–53.6) | ||
| GG | 60.0 (29.3–100) | 0.15 | |
|
rs4364254 (insulator) |
TT | 39.3 (34.1–45.4) | 5.16 |
| TC | 43.7 (37.9–50.4) | ||
| CC | 28.5 (20.3–39.9) | 0.076 | |
| rs4693608 | HR | 47.1 (40.4–55.1) | 18.04 |
| rs4364254 | MR | 41.1 (35.5–47.5) | |
| LR | 27.6 (21.6–35.3) | 0.00012 | |
| rs4693608 | N-HR | 49.2 (43.1–56.0) | 30.67 |
| rs4426765 | N-MR | 39.6 (33.9–46.4) | |
| rs4364254 | N-LR | 22.5 (16.5–30.7) | <0.00001 |
| Discrepancy | D1: N-HR/N-MR | 56.9 (47.6–68.1) | 33.67 |
| N-HR/N-LR | |||
| D2: N-HR/N-HR | 42.1 (36.8–48.0) | <0.00001 | |
| N-MR/N-MR | |||
| N-MR/N-HR | |||
| N-MR/N-LR | |||
| D3: N-LR/N-LR | 23.2 (17.1–31.5) | ||
| N-LR/N-MR | |||
| N-LR/N-HR |
Significant deviations (p < 0.05) are marked in bold. HR: AA-TT and AA-TC genotype combinations; MR: AG-TT and AG-TC genotype combinations; LR: GG-TT, GG-TC, GG-CC, and AG-CC genotype combinations. N-HR: AA-AA-TT, AA-AA-TC, AA-AC-TT, AA-AC-TC, AA-NN-NN, and AG-AA-TC genotype combinations (NN is any SNP genotype of rs4426765 and rs4364254 SNPs). N-MR: AG-AA-TT, AG-AC-TT, AG-AC-TC, AG-CC-TC, and GG-AA-TC genotype combinations. N-LR: GG-AA-TT, GG-AC-TT, GG-AC-TC, GG-AA-CC, GG-AC-CC, GG-CC-CC, and AG-NN-CC genotype combinations (NN is any SNP genotype of rs4426765).